With a legacy stretching back to 1983, Advarra® is the premier provider of institutional review board (IRB), institutional biosafety committee (IBC) and research quality and compliance consulting services in North America. Fully accredited by AAHRPP, Advarra serves the world’s leading pharmaceutical, biotechnology, medical device and contract research organizations, as well as academic medical centers, hospital systems, investigative site networks and therapeutic research consortia.
To address the increasingly complex needs associated with research, Advarra leverages exceptional client service, innovative technology and robust global regulatory expertise. Advarra also provides deep experience across all major therapeutic areas and continues to pioneer highly specialized review services for areas such as oncology and neurology.
Above all, Advarra provides integrated compliance services with unprecedented clarity, helping you navigate regulatory requirements more confidently.
Apply the highest standards of ethics and research compliance for the advancement of human health.
Be the global partner of choice for research compliance services and set the standard for ethical review, efficiency and thought leadership across the entire research continuum.
Advarra was formed in 2017 through the merger of the industry’s most respected IRBs, Chesapeake IRB and Schulman IRB, and is focused on increasing the quality and efficiency of IRB, IBC and compliance consulting services. We do so by leveraging our strengths in technology, regulatory expertise and customer service to address the increasingly complex needs associated with research.
Advarra sets the standard in quality, easy document accessibility and review turnaround time. We have enhanced our paperless, cloud-based submission and review platform, the Advarra Center for IRB Intelligence (CIRBI) Platform. Additionally, we are a leader in the protection of human research participants with expert therapeutic review services including Central Oncology Review (COR) and Central Neurology Review (CNR).